French Biotech AbTx Secures €1.7M Seed to Advance Miniaturised Cancer Antibodies

French biotech startup AbTx recently secured €1.7 million ($2 million) in seed funding to advance its miniaturized cancer antibodies. Launched in 2024, the company is dedicated to developing precision therapies for solid tumors that have resisted conventional treatments. The newly acquired funds will be dedicated to clinical development of AbTx's patented Therano-Stick platform, which employs enzymatic bio-conjugation to produce miniaturized antibody-drug conjugates (FDCs).

The Therano-Stick platform's enzymatic bio-conjugation process offers a distinct manufacturing advantage over competitors, positioning AbTx for differentiation in the crowded biotech landscape. This strategic move comes after the company received public validation through the prestigious i-Lab award, which further solidified its standing in the oncology sector.

Despite the relatively modest seed investment, AbTx now possesses sufficient capital to rigorously test its fragment drug conjugates in a highly competitive market. The funding allows the team to validate their technology and move closer to bringing miniaturized cancer antibodies to clinical trials, with the potential to revolutionize the treatment of solid tumors that have eluded standard therapies.